Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 202

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 202
---
 the first column. The numerator is based on the number of common shares set forth in the second column.

(3)Represents the closing price of the common shares on the Nasdaq Capital Market on February 7, 2025, the last trading day prior to the date of the SEPA.

<div align='center'>- 135 -

SELLING SHAREHOLDER</div>

This prospectus relates to the offer and sale by the Selling Shareholder of up to 3,710,000 common shares that have been and may be issued by us to the Selling Shareholder under the SEPA. We are registering the common shares being offered by this prospectus pursuant to the provisions of the SEPA we entered into with the Selling Shareholder on February 10, 2025 in order to permit the Selling Shareholder to offer such shares for resale from time to time. Except for the transactions contemplated by the SEPA, and as set forth in the section entitled "Plan of Distribution" in this prospectus, the Selling Shareholder has not had any material relationship with us within the past three years. As used in this prospectus, the term "Selling Shareholder" means YA II PN, Ltd., a Cayman Islands exempt limited company, and the pledgees, donees, transferees, assignees, successors, designees, and others who later come to hold any of the Selling Shareholder's interest in the common shares other than through a public sale.

The table below presents information regarding the Selling Shareholder and the common shares that may be resold by the Selling Shareholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Shareholder and reflects holdings as of May 21, 2025. The number of common shares in the column entitled "Maximum Number of Common Shares Being Offered" represents all of the common shares being offered for resale by the Selling Shareholder under this prospectus. The Selling Shareholder may sell some, all, or none of the shares being offered for resale in this offering. We do not know how long the Selling Shareholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling Shareholder and any other shareholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the common shares being offered for resale by this prospectus.

Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act